Latest
FDA's surprise Valentine Gift to WOMEN!
FDA's surprise Valentine Gift to WOMEN!
Who says FDA doesn't know anything about romance? We are pretty sure nothing like this ever happened before, the greatest romantic gesture in the history of FDA and the timing was priceless!
On Valentine eve FDA delivered a surprise gift, Ladies: its NOT long stem Roses, something Better! FDA said YES! to Gel. FDA has approved BioSante's Bio-T-Gel. BPAX estimates the market for Male Dysfunction drugs in the US alone is $1.2 Billion Dollars.
We alerted our members on Jan 17th when the stock was trading near the 52WK Lows, our headline read “BPAX shareholders wonder if there is a Gel for stock dysfunction!”
Well, there you have it, FDA answered the prayers and BPAX is UP a whopping 107% ! our members are ecstatic. Are you Gellin'?
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature, Always Read the full Disclosure/Disclaimer. Thanks.
DayStar Technologies | DSTI | Profile | Summary
DayStar - DSTI - is focused on low-cost, high performance, CIGS thin film photovoltaic products for converting electricity from the sun. The company aiming to achieve cost and performance parity with fossil fuel electricity generation.
Solar Photovoltaics
Solar cells work by absorbing light and converting it to electrical power, referred to as the photovoltaic effect. The majority of commercial solar cells in use today are made of silicon, the same semiconductor material used in the microelectronics industry. In addition to the semiconductor materials, solar cells consist of a top and bottom electrical contact to move the electricity out of the solar cell. The performance of a solar cell is measured in terms of its efficiency in converting sunlight into electricity. Typical commercial solar cells have an efficiency ranging between 6% and 18%, meaning that for every 1,000 watts of sunlight striking a solar module, 60 to 180 watts of electricity will be produced.
Thin Film Photovoltaics
Solar cells and modules made from certain thin film semiconductors have been shown to be much less expensive to produce in larger volume and requiring much less raw material to produce than silicon based PV cells. Extensive research and development on thin film cells has been conducted for more than 30 years, and recent advances in manufacturing and product commercialization have increased worldwide share of thin film photovoltaics to over 10% in 2007.
Thin film photovoltaic products exhibit the following attributes:
-
Scaleable, low cost manufacturing: Thin film solar cells and modules require a structural "substrate" to support them, such as glass. Applying the films on low cost glass substrates enables continuous and scaleable manufacturing. As much of the equipment to process these substrates is used in other industries, the capital expenditure required to establish large-volume thin film PV product manufacturing plants enables rapid capacity expansion and lowers the cost per watt of products.
-
Lower material cost: The substrate and raw materials used in thin film PV products are less expensive than the cost of most semiconductor materials. With increasing thin film manufacturing capacity and process yield improvements product costs are reduced.
-
Performance attributes: In addition to cost per watt advantages, thin film photovoltaic technologies exhibit performance advantages in generating energy in low light level and increased temperature environments. This positions them particularly well for applications in regions with less direct sunlight, such as in Northern Europe.
Day Start is trading near 52WK Lows, stock could Bounce back from this levels, keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.
CHGS, China Geng Sheng Minerals, Profile, Summary
Geng Sheng Minerals – CHGS - manufactures and markets a broad range of high-tech industrial material products, including monolithic refractories, industrial ceramics and fine precision abrasives. A market leader offering customized solutions.
Geng Sheng sells its products primarily to the iron and steel industry as heat-resistant components for steel-making furnaces, industrial kilns and other high-temperature vessels to guarantee and improve the productivity of those expensive pieces of equipment, while reducing their consumption of energy.
Geng Sheng's business is improving gradually, though at a very slow pace, as reported by the company. The stock is bouncing back from the 52WK LOWS, looks very interesting, keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.
Improving women's health and sex life, Bionovo, BNVI
Bionovo, BNVI, Profile, Summary
Bionovo (BNVI) a clinical-stage drug discovery and development company, focuses on the development drug candidates in the areas of women's health and cancer. The company's drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds.
Bionovo's lead drug candidate, Menerba, which completed phase 2 clinical trail and progressing into phase 3.
Improving Women’s Health
40 million women in America are of menopausal age, an estimated 75% to 85% experience significant and unpleasant side effects due to declining and fluctuating hormone levels. These problems include vaginal dryness, depression and weight gain. Existing therapies represent a multi-billion dollar market. Bionovo is striving to provide a safe, reliable, and clinically proven therapy to fill this unmet need.
The company also develops Bezielle, an oral anti-cancer agent that completed two separate phase 1 clinical trails for the treatment of advanced breast cancer. Seala, a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy.
Conquering Cancer
Breast cancer is the second leading cause of cancer deaths in the United States, and more than 200,000 new cases are diagnosed each year. As a result, breast cancer takes more than 40,000 lives annually.
The company successfully raised funds and appointed new executives and board members. The stock is trading near 52WK LOWS could bounce back, keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.
Feed Entries
